A multicentre, open-label, randomised trial to evaluate the tolerability and mechanism of action of IPH 1101 in antiviral-naive patients with chronic viral hepatitis C infections.

Trial Profile

A multicentre, open-label, randomised trial to evaluate the tolerability and mechanism of action of IPH 1101 in antiviral-naive patients with chronic viral hepatitis C infections.

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 07 Jul 2012

At a glance

  • Drugs Interleukin-2; IPH 1101
  • Indications Hepatitis C
  • Focus Therapeutic Use
  • Sponsors Innate Pharma
  • Most Recent Events

    • 07 Jul 2012 Inclusion and exclusion criteria amended from EudraCT.
    • 03 Jul 2012 Actual Initiation Date (19 Jun 2007) added as reported by European Clinical Trials Database
    • 02 Nov 2009 Results presented at the 60th Annual Meeting of the American Association for the Study of Liver Diseases.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top